Palopegteriparatide: Parathyroid Hormone Analog for the Treatment of Chronic Hypoparathyroidism in Adults
Lauren Lewis, Jackie Liu, Anu Sharma, Lihui YuanObjective:
To review the pharmacology, efficacy, and safety of palopegteriparatide for the treatment of chronic hypoparathyroidism in adults.
Data Sources:
A literature search was conducted in PubMed from September 2015 to August 2026. All relevant publications, package inserts, and clinical trials with palopegteriparatide were reviewed. Keywords used were: palopegteriparatide, hypoparathyroidism, parathyroid hormone (PTH), TransCon PTH, hypocalcemia, PTH(1-34), clinical trials and quality of life.
Data Extraction:
All relevant publications, abstracts, package inserts, and clinical trials involving palopegteriparatide were reviewed.
Data Synthesis:
Palopegteriparatide is a once-daily subcutaneous injection that uses TransCon technology to treat chronic hypoparathyroidism in adults. Palopegteriparatide led to 93% of participants achieving complete independence from conventional therapy (calcium and active vitamin D) in phase 3 trials. Pill burden decreased from 6.7 at baseline to 0.26 at week 52, and the health-related quality of life of participants significantly increased. The mild-to-moderate adverse effects of palopegteriparatide support its overall favorable tolerability profile.
Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:
Palopegteriparatide is a new PTH analog that mimics physiologic PTH exposure, resulting in more stable serum calcium levels and improved renal handling of calcium and phosphate.
Conclusion:
Palopegteriparatide is the only Food and Drug Administration-approved medication available that addresses PTH deficiency in chronic hypoparathyroidism. It provides a 24-hour continuous release of PTH enabling effective management of PTH insufficiency.